Taking the lead: RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Ltd. (NASDAQ: RDHL) stock fell -0.87% on Monday to $0.17 against a previous-day closing price of $0.17. With 2.28 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.25 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.1750 whereas the lowest price it dropped to was $0.1700. The 52-week range on RDHL shows that it touched its highest point at $3.27 and its lowest point at $0.13 during that stretch. It currently has a 1-year price target of $2.75. Beta for the stock currently stands at 2.13.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RDHL was down-trending over the past week, with a drop of -13.42%, but this was up by 0.59% over a month. Three-month performance dropped to -70.20% while six-month performance fell -80.32%. The stock lost -94.10% in the past year, while it has gained 21.88% so far this year.

Float and Shares Shorts:

At present, 63.84 million RDHL shares are outstanding with a float of 34.99 million shares on hand for trading. On Dec 29, 2022, short shares totaled 1.75 million, which was 1.92% higher than short shares on Nov 29, 2022. In addition to Mr. Dror Ben-Asher as the firm’s Co-Founder, Chairman & CEO, Mr. Micha Ben-Chorin serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 19.82% of RDHL’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.96% of RDHL, in contrast to 2.58% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in RDHL with 1.52% of the stake, Medical Strategy GmbH holds 1,381,299 shares worth 1,381,299. A second-largest stockholder of RDHL, Apo Asset Management GmbH, holds 876,112 shares, controlling over 0.96% of the firm’s shares. Millennium Management LLC is the third largest shareholder in RDHL, holding 623,892 shares or 0.68% stake. With a 1.28% stake in RDHL, the FCP Medical – BioHealth is the largest stakeholder. A total of 1,169,340 shares are owned by the mutual fund manager. The APO Medical Opportunities, which owns about 0.79% of RDHL stock, is the second-largest Mutual Fund holder. It holds 720,776 shares valued at 0.1 million. RIM Global – Bioscience holds 0.23% of the stake in RDHL, owning 211,959 shares worth 29674.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, RDHL reported revenue of $18.35M and operating income of -$9.16M. The EBITDA in the recently reported quarter was -$5.58M and diluted EPS was -$0.20.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RDHL since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RDHL analysts setting a high price target of $1.00 and a low target of $1.00, the average target price over the next 12 months is $1.00. Based on these targets, RDHL could surge 488.24% to reach the target high and rise by 488.24% to reach the target low. Reaching the average price target will result in a growth of 488.24% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RDHL will report FY 2022 earnings on 03/14/2024. Analysts have provided yearly estimates in a range of -$0.07 being high and -$0.07 being low. For RDHL, this leads to a yearly average estimate of -$0.07. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. RedHill Biopharma Ltd. surprised analysts by -$0.05 when it reported -$0.06 EPS against a consensus estimate of -$0.01.

Leave a Comment

Your email address will not be published. Required fields are marked *